Original article
Caffeine-potentiated chemotherapy for metastatic osteosarcoma

https://doi.org/10.1007/s00776-009-1372-5Get rights and content

Abstract

Background

The prognosis for patients with metastatic osteosarcoma is still poor despite the development of effective adjuvant and neoadjuvant chemotherapy regimens. We have developed caffeine-potentiated chemotherapy for treatment of high-grade bone and soft tissue sarcomas based on the ability of caffeine to enhance the cytocidal effects of anticancer drugs. We report results of caffeine-potentiated chemotherapy for patients with osteosarcoma with pulmonary metastases.

Methods

We analyzed retrospectively overall survival and some prognostic factors for 41 patients with osteosarcoma/ pulmonary metastases who were treated with caffeine-potentiated chemotherapy between 1990 and 2006.

Results

The mean follow-up of all patients was 32.7 months. At the time of the final follow-up, 11 patients were alive and 30 had died of disease. Overall survival rates at 2 and 5 years were 38% and 28%, respectively. We identified the primary tumor site, the histological response to preoperative chemotherapy, the number of pulmonary nodules at initial identification, the timing of pulmonary metastasis identification, and the existence of extrapulmonary metastasis as prognostic factors. Especially, the number of pulmonary nodules at initial identification and the timing of pulmonary metastasis identification were independent, strong prognostic factors. Patients with solitary pulmonary metastasis had good prognoses, and their overall 5-year survival rate was 60%; in contrast, survival was 28% in patients with two to five pulmonary nodules, and no patients with more than six nodules survived 5 years. Patients with pulmonary metastasis identified after completion of treatment had the best prognosis, whereas patients with pulmonary metastases identified during treatment had the worst prognosis.

Conclusions

Caffeine-potentiated chemotherapy prolonged survival of patients who had osteosarcoma with pulmonary metastasis. Especially, patients with pulmonary metastasis identified after completion of treatment or with a solitary pulmonary nodule had good prognoses.

References (23)

  • P.A. Meyers et al.

    osteogenic sarcoma with clinically detectable metastasis at initial presentation

    J Clin Oncol

    (1993)
  • S.S. Bielack et al.

    Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols

    J Clin Oncol

    (2002)
  • G. Bacci et al.

    Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy

    J Chemother

    (1998)
  • H. Tsuchiya et al.

    Effect of chemotherapy combined with caffeine for osteosarcoma

    J Cancer Res Clin Oncol

    (1992)
  • H. Tsuchiya et al.

    Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma

    Anticancer Res

    (1998)
  • H. Tsuchiya et al.

    Marginal excision for osteosarcoma with caffeine assisted chemotherapy

    Clin Orthop

    (1999)
  • A. Takeuchi et al.

    Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome

    Anticancer Res.

    (2007)
  • H. Sumiya et al.

    Midcourse thallium-201 scintigraphy to predict tumor response in bone and soft-tissue tumors

    J Nucl Med.

    (1998)
  • J. Taki et al.

    Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: comparison with Tl-201 imaging

    J Orthop Res

    (2008)
  • G. Rosen et al.

    Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

    Cancer

    (1982)
  • H. Tsuchiya et al.

    Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study

    J Clin Oncol

    (2002)
  • Cited by (26)

    • Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic

      2020, European Journal of Pharmacology
      Citation Excerpt :

      Methylxanthines have been widely used for therapeutic purposes for decades, with proven therapeutic benefits in different medical scopes. For example, the naturally occurring methylxanthines like caffeine, theophylline, and theobromine have been used in the treatment of respiratory diseases (Lam and Newhouse, 1990), cardiovascular diseases, cancer (Hayashi et al., 2005; Kimura et al., 2009) and the commercially produced xanthine derivative drug like pentoxifylline has been widely documented to have immunomodulatory properties including the downregulation of Tumour Necrosis Factor (TNF) α to treat the injurious effects due to immune activation in the syndrome of chronic heart failure (CHF) (Shaw et al., 2009). Pentoxifylline and its active metabolites enhance blood flow by decreasing blood viscosity and ameliorating erythrocyte flexibility.

    • Recent progress in natural dietary non-phenolic bioactives on cancers metastasis

      2018, Journal of Food and Drug Analysis
      Citation Excerpt :

      Zerumbone blocked the pancreatic cancer PaCa cells-associated angiogenesis through the inhibition of NF-κB and NF-κB-dependent proangiogenic gene products [143]. Caffeine-potentiated chemotheraphy consisting of 1.5 g caffeine/m2/day has been demonstrated to potentially prevent local recurrence or metastasis in patients with metastatic lung adenocarcinoma and prolong the survival rate of osteosarcoma patients with pulmonary metastasis [144,145]. Moreover, caffeine-potentiated chemotheraphy (1.5 g caffeine/m2/day) applied to five patients with clear cell sarcorma also decreased the risk for metastasis (distant metastasis newly developed in only one patient) [146].

    • Evaluation of anticancer effects and enhanced doxorubicin cytotoxicity of xanthine derivatives using canine hemangiosarcoma cell lines

      2013, Research in Veterinary Science
      Citation Excerpt :

      Therefore, caffeine has two anticancer effects and the ability to enhance anticancer drugs by inhibiting DNA repair pathways (Valenzuela et al., 2000). Several reports have indicated that caffeine has been utilized with chemotherapy for bone and soft tissue sarcoma (Hayashi et al., 2005; Kimura et al., 2009; Takeuchi et al., 2007). High doses of caffeine (1.5 g/m2) have been administered in caffeine-assisted chemotherapy (Karita et al., 2011; Tsuchiya et al., 1998, 1999) and induced a complete response in more than 80% of the observed patients (Tsuchiya et al., 1999) and enhanced the 5-year survival rate to approximately 90% (Tsuchiya et al., 1998).

    • Interferon-α/β receptor as a prognostic marker in osteosarcoma

      2011, Journal of Bone and Joint Surgery
      Citation Excerpt :

      After 1997, we used two established chemotherapy regimens. The NECO-95J16 and K217 protocols were used for twelve patients between 1997 and 2002 and for seven patients between 2002 and 2006. All biopsy samples used for the immunohistochemical analysis were reviewed to confirm the diagnosis of high-grade osteosarcoma.

    View all citing articles on Scopus
    View full text